… for its potential to treat MASH in the ongoing ESSENCE trial ( NCT04822181).Methods ESSENCE, a phase 3 trial involving 1200 participants w…
All extracted funders
Showing 1,201–1,260 of 3,238, ordered by supporting articles. Choose a funder to see its evidence.
Articles mentioning funders
5,089 articles · page 369 of 425…ancet commission prioritises earlier diagnosis of fibrosis with NHS community pilots underway. We aimed to evaluate the performance…
…s are common symptoms in PBC. In the phase III ELATIVE® trial ( NCT04526665), elafibranor significantly improved biomarkers of cholestasis …
…iomarkers assessed to Week 52 in the phase III ELATIVE® trial ( NCT04526665).Patients (N=161) were randomized 2:1 to elafibranor 80 mg or p…
…LF]) and biochemical markers in patients with PBC in ELATIVE® ( NCT04526665) to Week 104; NITs are also stratified by disease stage.Proport…
…st risk to develop HCC, British Society of Gastroenterology and National Institute for Health and Care Excellence guidelines recommend 6-monthly US surveillance with/without AFP…
… the development of standardised HCC surveillance strategies in Trusts, with dedicated surveillance databases now being created, in ad…
…se. 1 The American Association for the Study of Liver Diseases (AASLD) makes a recommendation for IV L-ornithine L-Aspartate (LOLA) t…
…rdise early interventions and improve cirrhosis management, our Trust adapted the British Society of Gastroenterology evidence-based …
…tric assessment.South London and Maudsley NHS Foundation Trust (SLaM) is an international leader in mental health and is the largest…
…mission for performance of the study has been obtained from the Ethics Review Board at each participating centre. We plan to disseminate the findin…
…by the Medical Research Ethics Committee Leiden-Den Haag-Delft, EU-trial-number 2023-510186-98. Study results will be disseminated through peer-reviewed journ…